QGQujia Gama

Qujia Gama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qujia Gama has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Sijia Liu

    Department of Gynecology Obstetrics and Gynecology Hospital of Fudan University Shanghai China

    2 shared publications
  • Bingyi Yang

    Department of Gynecology Obstetrics and Gynecology Hospital of Fudan University Shanghai China

    1 shared publication
  • Hongwei Zhang

    Shanghai Key Laboratory of Female Reproductive Endocrine‐Related Diseases Fudan University Shanghai China

    1 shared publication
  • Hongwei Zhang

    Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Shanghai, China

    1 shared publication
  • Li Sun

    Shanghai Key Laboratory of Female Reproductive Endocrine‐Related Diseases Fudan University Shanghai China

    1 shared publication
  • Li Sun

    Fujitsu Research and Development Center

    1 shared publication

Latest Publications

  • Effects of levonorgestrel‐releasing intrauterine system on recurrence and fertility outcomes during assisted reproduction after complete remission of early endometrioid endometrial cancer and precancerous lesions: A retrospective cohort study

    by Qujia Gama, Lulu Wang, Pengfei Wu, Sijia Liu, Bingyi Yang, Hongwei Zhang, Li Sun, Yiqin Wang, Xuezhen Luo, Min Yu, et al.

    To investigate the efficacy of the levonorgestrel‐releasing intrauterine system (LNG‐IUS) on recurrence and fertility outcomes during controlled ovarian stimulation (COS) in patients with early stage endometrioid endometrial carcinoma (EEC) and endometrial atypical hyperplasia (EAH) following successful fertility‐preserving treatment. We reviewed the patients with Grade 1 presumed Stage IA EEC or EAH who underwent in vitro fertilization and embryo transfer after successful fertility‐sparing treatment. A total of 176 women were enrolled in this study, undergoing 318 cycles of COS and 290 cycles of embryo transfer (ET). Twenty‐one percent (37/176) patients have an LNG‐IUS insertion during the initial ovarian stimulation, and the median follow‐up time for this cohort was 61.3 months (interquartile range [IQR], 39.0–76.6 months), while it was 60.5 months for the other cohort (IQR, 44.9–80.3 months). Disease recurrence was experienced by 34.7% (61/176) of the patients. Compared to the non‐LNG‐IUS group, the LNG‐IUS group had a lower recurrence rate 1 year after COS (5.4% (2/37) versus 20.9% (29/139), p = .034). The use of LNG‐IUS was associated with a reduced recurrence rate 1 year after COS (hazard ratio = 0.203, 95% confidence interval [0.042–0.984], p = .048). The overall clinical pregnancy rate reached as high as 65.3% (115/176), while the cumulative live birth rates were up to 46.6% (85/176). We found that LNG‐IUS during COS did not impact oocyte yield, ET, or pregnancy outcomes. The placement of LNG‐IUS during COS in EEC/EAH patients is worth considering, as it is likely to reduce the recurrence of endometrial lesions without affecting fertility outcomes.


  • Open Access

    The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary

    by Qujia Gama, Shuhan Luo, Pengfei Wu, Lulu Wang, Sijia Liu, Hongwei Zhang, Li Sun, Yiqin Wang, Min Yu, Xiaojun Chen, et al.

    To investigate the efficacy of fertility-preserving treatment for young women with synchronous primary neoplasm of endometrium and ovary. We retrospectively reviewed eight patients with concurrent primary grade 1 presumed stage IA endometrioid endometrial adenocarcinoma (EEA) or endometrial atypical hyperplasia (EAH) and primary stage I ovarian tumors who underwent fertility-sparing treatment in the Obstetrics and Gynecology Hospital of Fudan University between April 2016 and December 2022. Synchronous endometrial and ovarian cancers (SEOC) accounted for 50% of these eight patients. The median age of patients was 30.5 years (range, 28–34 years). None of them received chemotherapy. The median treatment time was 4 months (range, 3–8 months). 87.5% (7/8) cases achieved complete response (CR), and the median time to CR was 3.8 months (range, 1.5–7.7 months). Among patients who got CR, none of them showed any signs of recurrence. Pregnancies and successful deliveries were achieved in 4 of 5 patients. Till September 2023, the median follow-up period was 50.5 months (range:15.2–85.2 months). Fertility-sparing treatment is feasible for highly selected patients with synchronous neoplasm of the endometrium and ovary, but strict screening and monitoring are mandatory. Though the results of our limited cases are encouraging, long follow-up and more clinical data are required. Enrolled patients must be fully informed of the risks during conservative treatment.